Good morning, everyone, and how are you today? We are doing just fine, thank you, as a hazy sky is giving way to a bit of sunshine and a soothing quiet has descended on the Pharmalot campus. Of course, we are busy as ever, foraging for interesting items. Summer may be upon us, but the world continues to spin, even if the ride is a bit rocky at times. So please join us for a cup of stimulation to restore some equilibrium. Meanwhile, here are a few tidbits for you. Hope your day is simply smashing and do drop us a line when you come across something confidential …

A group of Takeda Pharmaceutical (TKPYY) shareholders who are trying to block the $62 billion acquisition of Shire (SHPG) failed to get a proposal passed at the drug maker’s annual general meeting, Reuters reports. The proposal — to require advance shareholder approval for large acquisitions — received 10 percent of votes. But the 130-member group formed by ex-Takeda employees is also working to persuade one-third of shareholders to vote against a company proposal at an upcoming Takeda shareholder meeting to approve an issue of new stock to help fund the Shire deal.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy